How the Lysophospholipid Got its Receptor

How the Lysophospholipid Got its Receptor The discovery of a new family of lipid receptors provides potential targets for diseases such as multiple sclerosis and autoimmunity. By Jerold Chun Related Articles 1 By the late 1960s, researchers had become aware that this somewhat obscure class of lipids had the remarkable ability to act like an extracellular signaling molecule.2 Two prominent forms typify but do not limit lysophospholipids: lysophosphatidic acid

Written byJerold Chun
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

By Jerold Chun

1 By the late 1960s, researchers had become aware that this somewhat obscure class of lipids had the remarkable ability to act like an extracellular signaling molecule.2 Two prominent forms typify but do not limit lysophospholipids: lysophosphatidic acid (LPA), which is derived from glycerophospholipids such as phosphatidyl serine or phosphatidyl choline (known commonly as lecithin, as in egg yolk); and sphingosine 1-phosphate (S1P), which is derived from sphingolipids such as sphingomyelin, ceramide, and sphingosine.

Although rare compared to most membrane lipids, they could be found in relatively high concentrations (micromolar) within blood plasma and/or serum. How these lysophospholipids worked was unclear and much debated in the decade preceding the mid-1990s, with explanations invoking lysophospholipids as membrane disruptors (lysophospholipids look a bit like detergents), second messengers, ionophores, calcium chelators, as well as ligands for intracellular and extracellular receptors.

"We had found a gene and the GPCR it encoded, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies